Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

Exclusion Criteria

• •History or presence of type 1 diabetes mellitus or a history of ketoacidosis
• •History of other specific types of diabetes (eg, genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant).
• •A known hypersensitivity or intolerance to any sodium-glucose co-transporter 2 (SGLT2) inhibitor
• •Use of the following prohibited therapeutic agents within 12 weeks of study participation: insulin, injectable anti-hyperglycemic agents, pioglitazone or rosiglitazone, another SGLT2 inhibitor, bromocriptine (Cycloset®), colesevelam (Welchol®), and any other non-approved anti-hyperglycemic therapy
• •Known hypersensitivity or intolerance to metformin or glimepiride
• •On a weight-loss program or medication or medication associated with weight changes and is not weight-stable (\>=5% change in body weight in the last 6 months)
• •History of bariatric surgery less than 12 months prior to study participation
• •History of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA) functional class III-IV heart failure within 3 months of study participation
• •Active, obstructive uropathy or an indwelling urinary catheter
• •A history of malignancy ≤5 years prior to study participation, except for adequately treated basal or squamous cell skin cancer or in situ cervical cancer
• •Known history of Human Immunodeficiency Virus (HIV)
• •Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells
• •A medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C (assessed by medical history), primary biliary cirrhosis, or symptomatic gallbladder disease
• •Any clinically significant malabsorption condition
• •Being treated for hyperthyroidism, or on thyroid replacement therapy that has not been at a stable dose for at least 6 weeks prior to study participation
• •Previous randomization in a study with ertugliflozin
• •Participation in other studies involving investigational drug(s) within 30 days of study participation and/or during the pre-randomization period
• •A surgical procedure within 6 weeks prior to study participation or planned major surgery during the trial
• •A positive urine pregnancy test
• •Pregnant or breast-feeding, or expecting to conceive during the trial, including 14 days following the last dose of study drug
• •Undergoing hormonal therapy in preparation to donate eggs during the period of the trial, including 14 days following the last dose of study drug
• •Consumption of more than 2 alcoholic drinks per day or engages in binge drinking
• •Donation of blood or blood products within 6 weeks of study participation or plans to donate blood or blood products at any time during the trial